FREGA, GIORGIO
FREGA, GIORGIO
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
2023 Vasuri, Francesco; Deserti, Marzia; Corradini, Angelo G; Tavolari, Simona; Relli, Valeria; Palloni, Andrea; Frega, Giorgio; Curti, Stefania; Mattioli, Stefano; Cescon, Matteo; D'Errico, Antonia; Brandi, Giovanni
NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report
2023 Palmerini E.; Frega G.; Gambarotti M.; Frisoni T.; Cesari M.; Bazzocchi A.; Miceli M.; Donati D.M.; Fanti S.; Nanni C.; Benini S.; Longhi A.; Paioli A.; Marrari A.; Hakim R.; Righi A.; Ibrahim T.
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
2023 Palloni, Andrea; Bisello, Silvia; Maggio, Ilaria; Massucci, Maria; Galuppi, Andrea; Di Federico, Alessandro; Rizzo, Alessandro; Ricci, Angela Dalia; Siepe, Giambattista; Morganti, Alessio Giuseppe; Brandi, Giovanni; Frega, Giorgio
Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study
2022 Palmerini E.; Pazzaglia L.; Cevolani L.; Pratelli L.; Pierini M.; Quattrini I.; Carretta E.; Manara M.C.; Pasello M.; Frega G.; Paioli A.; Longhi A.; Cesari M.; Hakim R.; Ibrahim T.; Campanacci L.; Staals E.L.; Donati D.M.; Benassi M.S.; Scotlandi K.; Ferrari S.
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
2022 Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi.
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma
2022 Brandi G.; Di Federico A.; Rizzo A.; De Lorenzo S.; Vasuri F.; Brocchi S.; Golfieri R.; Morelli M.C.; Frega G.; Palloni A.
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis
2021 Filippi R.; Leone F.; Fornaro L.; Aprile G.; Casadei-Gardini A.; Silvestris N.; Palloni A.; Satolli M.A.; Scartozzi M.; Russano M.; Lutrino S.E.; Lombardi P.; Frega G.; Garattini S.K.; Vivaldi C.; Spadi R.; Giulia O.; Fenocchio E.; Brunetti O.; Aglietta M.; Brandi G.
Experimental HER2- targeted therapies for biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Bonucci C.; Tober N.; Palloni A.; Frega G.; Brandi G.
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue
2021 Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G.
Hacking pancreatic cancer: Present and future of personalized medicine
2021 Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Marco M.; Palloni A.; Brandi G.
Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms
2021 G. Frega, O. Kepp, D. Turchetti, A. Rizzo, M.A. Pantaleo, G. Brandi
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience
2021 Rizzo, A.; Frega, G.; Palloni, A.; Piemontese, A.; Di Federico, A.; Ricci, A.; Carloni, R.; Fabbri, F.; Novelli, M.; Tavolari, S.; Di Marco, M.; Ravaioli, M.; Brandi, G.
Nivolumab: an investigational agent for the treatment of biliary tract cancer
2021 Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G.
Second-line FOLFOX chemotherapy for advanced biliary tract cancer
2021 Brandi G.; Frega G.; Rizzo A.
The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?
2021 Giovanni Brandi; Silvia Turroni; Florencia McAllister; Giorgio Frega
The human microbiomes in pancreatic cancer: Towards evidence-based manipulation strategies?
2021 Brandi, G.; Turroni, S.; Mcallister, F.; Frega, G.
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis
2020 Rizzo A.; Frega G.; Ricci A.D.; Palloni A.; Abbati F.; de Lorenzo S.; Deserti M.; Tavolari S.; Brandi G.
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
2020 Frega G.; Palloni A.; Di Pasquale G.; Saccoccio G.; Rizzo A.; Poluzzi E.; Iannone P.; Brandi G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study | Vasuri, Francesco; Deserti, Marzia; Corradini, Angelo G; Tavolari, Simona; Relli, Valeria; Pallon...i, Andrea; Frega, Giorgio; Curti, Stefania; Mattioli, Stefano; Cescon, Matteo; D'Errico, Antonia; Brandi, Giovanni | 2023-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | 70-Vasuri et al_Sci Rep 2023.pdf; 41598_2023_27791_MOESM1_ESM.pdf |
| NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report | Palmerini E.; Frega G.; Gambarotti M.; Frisoni T.; Cesari M.; Bazzocchi A.; Miceli M.; Donati D.M....; Fanti S.; Nanni C.; Benini S.; Longhi A.; Paioli A.; Marrari A.; Hakim R.; Righi A.; Ibrahim T. | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | fonc-13-1252359.pdf |
| The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma | Palloni, Andrea; Bisello, Silvia; Maggio, Ilaria; Massucci, Maria; Galuppi, Andrea; Di Federico, ...Alessandro; Rizzo, Alessandro; Ricci, Angela Dalia; Siepe, Giambattista; Morganti, Alessio Giuseppe; Brandi, Giovanni; Frega, Giorgio | 2023-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | curroncol-30-00358.pdf; curroncol-30-00358-s001.zip |
| Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study | Palmerini E.; Pazzaglia L.; Cevolani L.; Pratelli L.; Pierini M.; Quattrini I.; Carretta E.; Mana...ra M.C.; Pasello M.; Frega G.; Paioli A.; Longhi A.; Cesari M.; Hakim R.; Ibrahim T.; Campanacci L.; Staals E.L.; Donati D.M.; Benassi M.S.; Scotlandi K.; Ferrari S. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-02863-v2 (1).pdf |
| Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? | Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, An...drea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavo...lari S.; Di Marco M.; Palloni A.; Brandi G. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | articolo 2022 Immunotherapy in Pancreatic Cancer Why Do We Keep Failing A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.pdf |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De G...iglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-02429 (1).pdf |
| The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma | Brandi G.; Di Federico A.; Rizzo A.; De Lorenzo S.; Vasuri F.; Brocchi S.; Golfieri R.; Morelli M....C.; Frega G.; Palloni A. | 2022-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
| Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis | Filippi R.; Leone F.; Fornaro L.; Aprile G.; Casadei-Gardini A.; Silvestris N.; Palloni A.; Satol...li M.A.; Scartozzi M.; Russano M.; Lutrino S.E.; Lombardi P.; Frega G.; Garattini S.K.; Vivaldi C.; Spadi R.; Giulia O.; Fenocchio E.; Brunetti O.; Aglietta M.; Brandi G. | 2021-01-01 | JOURNAL OF CHEMOTHERAPY | - | 1.01 Articolo in rivista | - |
| Experimental HER2- targeted therapies for biliary tract cancer | Rizzo A.; Ricci A.D.; Bonucci C.; Tober N.; Palloni A.; Frega G.; Brandi G. | 2021-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue | Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G. | 2021-01-01 | EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | - | 1.01 Articolo in rivista | - |
| Hacking pancreatic cancer: Present and future of personalized medicine | Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Mar...co M.; Palloni A.; Brandi G. | 2021-01-01 | PHARMACEUTICALS | - | 1.01 Articolo in rivista | Hacking Pancreatic.pdf |
| Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms | G. Frega, O. Kepp, D. Turchetti, A. Rizzo, M.A. Pantaleo, G. Brandi | 2021-01-01 | TRANSLATIONAL ONCOLOGY | - | 1.01 Articolo in rivista | Frega,2021.pdf |
| Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience | Rizzo, A.; Frega, G.; Palloni, A.; Piemontese, A.; Di Federico, A.; Ricci, A.; Carloni, R.; Fabbr...i, F.; Novelli, M.; Tavolari, S.; Di Marco, M.; Ravaioli, M.; Brandi, G. | 2021-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | Annals_of_Oncology_21.pdf |
| Nivolumab: an investigational agent for the treatment of biliary tract cancer | Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G. | 2021-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| Second-line FOLFOX chemotherapy for advanced biliary tract cancer | Brandi G.; Frega G.; Rizzo A. | 2021-01-01 | THE LANCET ONCOLOGY | - | 1.04 Replica / breve intervento (e simili) | - |
| The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies? | Giovanni Brandi; Silvia Turroni; Florencia McAllister; Giorgio Frega | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | The Human Microbiomes in.pdf |
| The human microbiomes in pancreatic cancer: Towards evidence-based manipulation strategies? | Brandi, G.; Turroni, S.; Mcallister, F.; Frega, G. | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | Brandi et al., 2021.pdf |
| Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis | Rizzo A.; Frega G.; Ricci A.D.; Palloni A.; Abbati F.; de Lorenzo S.; Deserti M.; Tavolari S.; Br...andi G. | 2020-01-01 | IN VIVO | - | 1.01 Articolo in rivista | - |
| Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements | Frega G.; Palloni A.; Di Pasquale G.; Saccoccio G.; Rizzo A.; Poluzzi E.; Iannone P.; Brandi G. | 2020-01-01 | FRONTIERS IN PHARMACOLOGY | - | 1.01 Articolo in rivista | fphar-11-559996.pdf |